ImmuPharma

ImmuPharma EBIT per Employee

The EBIT per Employee of ImmuPharma (IMM.L) as of Nov 22, 2026 is -149,571.71 GBP. In the previous year, EBIT per Employee was -157,370.82 GBP — a change of -4.96% (higher).

EBIT per Employee

-149,571.71GBP

YoY

-4.96%

Last updated:

EBIT per Employee of ImmuPharma is 2025 -149,571.71 GBP. EBIT per Employee of ImmuPharma was 2024 -157,370.82 GBP. It decreases by -4.96% higher compared to the previous year.

The ImmuPharma EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-475,294.12 GBP
Jan 1, 2019
-369,529.41 GBP
Jan 1, 2020
-328,764.71 GBP
Jan 1, 2021
-387,470.59 GBP
Jan 1, 2022
-178,176.47 GBP
Jan 1, 2023
-180,176.47 GBP
Jan 1, 2024
-157,370.82 GBP
Jan 1, 2025
-149,571.71 GBP
The ImmuPharma EBIT per Employee history
YEAREBIT per EmployeeYoY
-149,571.71GBP-4.96%
-157,370.82GBP-12.66%
-180,176.47GBP+1.12%
-178,176.47GBP-54.02%
-387,470.59GBP+17.86%
-328,764.71GBP-11.03%
-369,529.41GBP-22.25%
-475,294.12GBP+11.69%
-425,529.41GBP+9.79%
-387,588.24GBP+44.40%
-268,411.76GBP+33.23%
-201,470.59GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuPharma Stock analysis

What does ImmuPharma do? ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuPharma stock

EBIT per Employee of ImmuPharma is -149,571.71 GBP in 2025.

EBIT per Employee of ImmuPharma changed from -157,370.82 GBP to -149,571.71 GBP, representing a -4.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee ImmuPharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's ImmuPharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ImmuPharma

All Key Metrics — ImmuPharma